艾沙度林治疗腹泻型肠易激综合征的安全性
本文汇总分析了一项2期(IBS-2001)和两项3期(IBS-3001、IBS-3002)研究中艾沙度林75 mg和100 mg每日两次治疗腹泻型肠易激综合征(IBS-D)的安全性数据。安全性集共2814例患者,最常见不良事件为便秘和恶心,疑诊Oddi括约肌痉挛(SOS)事件10例(0.5%),全部发生于无胆囊患者,且多数(8例)发生于高剂量组、开始治疗后1周内,停药后均缓解。
要点
- 艾沙度林75 mg和100 mg每日两次治疗IBS-D总体耐受性良好,便秘和恶心为最常见不良事件。
- 疑诊Oddi括约肌痉挛事件10例(0.5%),全部发生于无胆囊患者,8例发生于100 mg高剂量组。
- SOS事件多在开始治疗后1周内出现,停药后均缓解;另有5例独立判定为胰腺炎,其中3例与大量饮酒相关。
核心结论
- 艾沙度林在2期和3期试验中耐受性良好,便秘和恶心为最常见不良事件。
- 与阿片受体激动剂的已知不良反应一致,艾沙度林治疗患者中观察到临床明显的SOS事件,全部发生于无胆囊患者,多数见于较高剂量组,提示可能存在关联。
研究设计与样本
- 汇总分析一项2期研究(IBS-2001)和两项3期研究(IBS-3001、IBS-3002)的安全性数据。
- 成人IBS-D患者(符合Rome III标准)随机接受安慰剂或艾沙度林75 mg或100 mg每日两次,疗程分别为12周(IBS-2001)、26周(IBS-3002)或52周(IBS-3001)。
- 入组集2776例患者,安全性集基于实际接受的治疗共2814例患者。
主要发现
- 安慰剂组、艾沙度林75 mg组和100 mg组最常见不良事件分别为便秘(2.5%、7.4%、8.1%)和恶心(5.0%、8.1%、7.1%)。
- 因便秘停药的比例分别为0.3%、1.1%和1.5%。
- 艾沙度林治疗患者中发生10例SOS事件(10/1839;0.5%),表现为急性腹痛伴转氨酶或脂肪酶升高,或胰腺炎;全部发生于无胆囊患者。
- 10例SOS事件中8例发生于较高剂量组,且均在开始治疗后1周内出现,停药后全部缓解。
- 另有5例事件被独立判定为与SOS无关的胰腺炎,其中3例与大量饮酒相关。
关键数值与推荐
- 便秘发生率:安慰剂组2.5% vs 艾沙度林75 mg组7.4% vs 100 mg组8.1%。
- 恶心发生率:安慰剂组5.0% vs 艾沙度林75 mg组8.1% vs 100 mg组7.1%。
- 因便秘停药率:安慰剂组0.3% vs 艾沙度林75 mg组1.1% vs 100 mg组1.5%。
- SOS事件:艾沙度林治疗患者10/1839(0.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Eluxadoline is a mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist, approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D). This analysis evaluated the safety and tolerability of eluxadoline 75 and 100 mg twice daily (BID) in one Phase 2 (IBS-2001) and two Phase 3 (IBS-3001 and IBS-3002) studies. METHODS: Adults with IBS-D (Rome III criteria) were randomized to placebo or eluxadoline (75 or 100 mg) BID for 12 (IBS-2001), 26 (IBS-3002), or 52 (IBS-3001) weeks. Safety data were pooled. Adverse events (AEs) were assessed, with special focus on opioid-related AEs, including suspected sphincter of Oddi spasm (SOS) events. RESULTS: 2,776 patients were included in the enrolled set; the safety set comprised 2,814 patients, based on actual treatments received. The most frequent AEs in the placebo and eluxadoline 75 and 100 mg groups were constipation (2.5, 7.4, and 8.1%, respectively) and nausea (5.0, 8.1, and 7.1%, respectively); discontinuation due to constipation was uncommon (0.3, 1.1, and 1.5%, respectively). Ten SOS events (10/1,839; 0.5%) occurred in eluxadoline-treated patients, manifesting as acute abdominal pain with elevated aminotransferases or lipase, or pancreatitis; all occurred in patients without a gallbladder. Eight of these events occurred with the higher dose of eluxadoline, within 1 week of initiation of therapy, and all resolved with eluxadoline discontinuation. There were five events independently adjudicated as pancreatitis not associated with SOS, three of which were associated with heavy alcohol use. CONCLUSIONS: Eluxadoline was well tolerated in Phase 2 and 3 trials, with constipation and nausea the most common AEs. Consistent with the known adverse effects of opioid agonists, clinically apparent SOS events were observed in eluxadoline-treated patients. All occurred in patients without a gallbladder and the majority were observed in patients on the higher dose of eluxadoline, suggesting a possible association.
引用
- Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol. 2016. PMID: 27922029. doi:10.1038/ajg.2016.542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。